The rapid growth of artificial intelligence is creating significant opportunities for startups, investors, and technology companies. However, the excitement surrounding AI is also raising concerns about transparency, exaggerated claims, and the difficulty of distinguishing genuine innovation from technology that delivers little real value.
Tyler Shultz, a former Theranos employee who helped expose the company’s fraudulent blood-testing claims, is warning that today’s AI boom could create new opportunities for deception. His concerns highlight an important question for the technology industry: How can investors determine whether a promising AI startup has developed something genuinely innovative or is simply selling an impressive story?
Lessons From the Theranos Scandal
Theranos once attracted enormous attention and investment by promising to revolutionize medical testing. Founded by Elizabeth Holmes, the company claimed its technology could perform a wide range of blood tests using only a small amount of blood.
The company’s valuation eventually reached approximately $10 billion, attracting wealthy investors and prominent supporters. However, its technology failed to deliver on its promises, and the company relied on conventional laboratory equipment for many tests.
The consequences extended beyond financial losses. Inaccurate testing results created serious concerns about patient safety, while investigations eventually exposed the company’s misleading claims.
Shultz, who worked at Theranos after graduating from college, became a key whistleblower after discovering problems with its testing technology. His experience provides a firsthand perspective on how persuasive leadership, secrecy, and investor enthusiasm can allow questionable businesses to gain credibility.
Why Artificial Intelligence Creates New Risks
According to Shultz, evaluating AI companies can be particularly difficult because the technology is complex and rapidly evolving. Investors may struggle to determine whether a startup has developed a genuinely differentiated product or simply built an application around an existing AI model.
For example, a company might market its platform as a revolutionary AI solution while relying heavily on technology developed by established providers. Although building on existing models is not inherently problematic, the distinction matters when a startup makes claims about its proprietary technology, competitive advantages, or long-term commercial potential.
The challenge becomes more significant when investors must evaluate technical capabilities they cannot easily verify themselves.
In a market where AI businesses can attract substantial funding based on ambitious promises, impressive demonstrations and confident presentations may receive more attention than independent evidence of product performance.
This creates an environment in which misleading claims could go undetected unless investors conduct thorough technical and commercial assessments.
Investors Must Look Beyond Compelling Presentations
The Theranos case demonstrated how personal relationships and persuasive storytelling can influence investment decisions. Shultz believes investors should be more cautious about committing substantial amounts of money without sufficient verification.
For AI startups, due diligence should extend beyond market forecasts, product demonstrations, and leadership credentials.
Investors should examine whether a product performs as advertised, understand which technologies it depends on, and assess whether its claimed advantages can be independently demonstrated. They should also evaluate customer adoption, revenue quality, operating costs, and the sustainability of the business model.
Technical experts can help investors understand the difference between a meaningful technological breakthrough and a product that offers limited differentiation.
Transparency is equally important. Companies that refuse to provide reasonable evidence supporting their claims should face additional scrutiny, particularly when seeking large investments.
The Importance of Accountability in the AI Era
The concerns surrounding AI investment are emerging alongside enormous valuations and continued fundraising across the technology sector. While high valuations do not automatically indicate misconduct, they can increase pressure on startups to demonstrate growth and justify investor expectations.
This makes accountability essential for maintaining confidence in the industry.
AI companies must communicate their capabilities honestly, acknowledge limitations, and avoid presenting experimental features as fully developed solutions. Investors, meanwhile, need to distinguish genuine technical progress from promotional narratives.
The Theranos scandal also illustrates why whistleblowers matter. Employees who identify serious problems can provide crucial information that investors, customers, and regulators might otherwise overlook. Organizations should establish channels through which concerns can be raised without fear of retaliation.
A Cautionary Lesson for the Future of AI
Shultz’s warning is not an argument against artificial intelligence or startup investment. Instead, it is a reminder that technological excitement should never replace evidence.
AI has the potential to transform industries, improve productivity, and create valuable products. Realizing that potential requires companies to earn trust through measurable results rather than ambitious promises alone.
As the industry continues to attract capital and attention, investors must apply the lessons of previous technology scandals. Careful verification, technical transparency, and accountability will be essential to separating sustainable innovation from businesses built primarily on hype.
Ultimately, the long-term success of the AI industry will depend not only on how powerful its technology becomes, but also on whether companies can demonstrate that their promises match reality.